Info

The Psychedelic Podcast

The Psychedelic Podcast connects you to the leaders and pioneers of the psychedelic renaissance. From deep healing to creativity, leadership to spirituality, business, health, human performance, relationships, sexuality, and even culture itself—every aspect of our world is being transformed by psychedelic medicines. Get an inspired, informed, balanced look into how these powerful medicines are already being safely and responsibly used to catalyze both personal and collective transformation. Whether you’re just curious or a seasoned psychonaut, or somewhere in between, you’ll get insightful, practical, cutting-edge conversations from the forefront of the psychedelic movement. Join us as we explore how psychedelics can be integrated into culture for the evolution of humanity.
RSS Feed Subscribe in Apple Podcasts
The Psychedelic Podcast
2023
October
September
August
July
June
May
April
March
February
January


2022
December
November
October
September
August
July
June
May
April
March
February
January


2021
December
October
September
August
June
May
April
March
February
January


2020
December
November
October
September
August
July
June
May
April
March
February
January


2019
December
November
October
January


2018
December
November
October
September
August
July
June
May
April
March
February
January


2017
August
July
June
May
April
March
February
January


All Episodes
Archives
Now displaying: May, 2023
May 29, 2023
Jeffrey Stevens, co-founder and CEO of Psyched Wellness, joins The Psychedelic Podcast to discuss Calm, North America's first legal supplement derived from Amanita muscaria.

Find episode links, summary, and transcript here.

Amanita muscaria mushrooms’ red-and-white speckled caps are emoji-level iconic. But most people don’t know that consuming low dosages can reduce stress levels, promote relaxation, and offer a restful sleep without next-day grogginess. Amanita extracts also possess anti-inflammatory properties that could significantly relieve pain. And that’s just the tip of the iceberg, according to Stevens.

As the episode unfolds, Stevens imagines the future of Amanita research for mental health, addiction, and insomnia, while revealing his life-changing experience as a Psyched Wellness guinea pig.

Jeffrey Stevens has 20+ years of capital markets’ experience and has been an officer and director with several public companies. He has taken three companies public via reverse takeover, built teams, and structured multiple M&A transactions, while building successful businesses.

Highlights:

  • The path to Psyched Wellness.
  • Why Psyched Wellness utilizes an Amanita extract vs. the whole mushroom.
  • Amanita muscaria history and lore.
  • Exploring the science of Amanita muscaria and Psyched Wellness’s “Calm” extract, AME-1.
  • Calm’s dose-dependent effects and benefits.
  • Anecdotal evidence on Amanita muscaria for sleep, gut health, and addiction.
  • Calm’s market advantage as a legal food supplement.
  • Jeffrey’s vision for Psyched Wellness’s future.
  • How Psyched Wellness is educating consumers about Amanita muscaria.

Key Links:

These show links may contain affiliate links. Third Wave receives a small percentage of the product price if you purchase through the above affiliate links.

Episode Sponsors:

Psyched Wellness - use code THIRDWAVE23 to get 15% off.

Third Wave's Mushroom Grow Kit

May 22, 2023

Graham Pechenik, founder and patent attorney at Calyx Law, joins The Psychedelic Podcast to delve into the complex world of patents and their impact on the psychedelic landscape. 

Find episode links, summary, and transcript here.

Pechenik raises thought-provoking questions about the patent system's role in fostering innovation while also potentially hindering research and restricting use. He suggests that the patent system, intertwined with regulatory and healthcare structures, often determines whether groundbreaking substances like psilocybin gain FDA approval. Pechenik also explores concerns surrounding excessive psychedelic patents, comparing the unique approaches of COMPASS Pathways, MAPS, and Paul Stamets. 

As the episode unfolds, Graham and Paul contemplate the delicate balance between patent protection and freedom of use in the burgeoning psychedelics industry.

Graham Pechenik is a registered patent attorney and the founder of Calyx Law, a law firm specializing in cannabis and psychedelics-related intellectual property. 

Graham has a BS from UC San Diego, where he chose Cognitive Neuroscience and Biochemistry majors—after his first psychedelic experiences inspired a deep curiosity about the bases for changes in consciousness—and a JD from New York University, where he initially pursued interests in bioethics and cognitive liberty. 

After a decade at large law firms defending and challenging patents for Fortune 500 companies across the agricultural, chemical, pharmaceutical, biotech, and technology industries, including working on several landmark patent cases both at trial and on appeal, Graham started Calyx Law in 2016 to help cannabis and psychedelics ventures design and implement their IP strategies. 

Graham is also editor-at-large of Psychedelic Alpha, where he writes about psychedelics IP, provides data for patent trackers, and maintains a psychedelics legalization and decriminalization tracker. He is the founding steward of the IP Committee of the Psychedelic Bar Association, where he is also on the Board of Directors, and is a member of Chacruna’s Council for the Protection of Sacred Plants. 

Graham was raised in Oakland, CA, and currently lives in San Francisco.

Highlights:

  • Examining the unique patent process for the Stamets Stack microdosing protocol.
  • How to enforce patents on illegal substances like psilocybin.
  • Unpacking COMPASS Pathways’ psilocybin polymorph patent.
  • The pros & cons of psychedelic patents.
  • How psychedelic patents could hinder therapeutic expansion.
  • Graham’s motivation to enter the psychedelic patents space.

Key Links:

Episode Sponsors:

May 15, 2023

In this episode of The Psychedelic Podcast, Dr. Daniel Stickler and Paul F. Austin explore the cutting-edge field of longevity and precision-performance medicine.

Find episode links, summary, and transcript here.

After over a decade as a general surgeon, Dr. Stickler abandoned modern medicine’s reductionist approach and forged a new path toward holistic health and optimization. He believes that addressing deficiency mindsets and focusing on purpose, love, and community can help people move beyond simply existing and truly thrive. Through his work, Dr. Stickler has discovered ways to reverse biological aging and help people achieve enhanced states of being.

Dr. Stickler shares his insights on how humans can live a life of excellence, the revolutionary field of gene-editing technology, and his transformative psychedelic experiences.

Dr. Daniel L. Stickler is the Co-Founder and Chief Medical Officer at Apeiron ZOH Inc. He is the pioneer behind systems-based, precision-performance medicine, a new paradigm that re-defines medicine from the old symptoms-based disease model to limitless peak performance and systems science in all aspects of life.

Highlights:

  • The need for complex systems-thinking in modern medicine.
  • Dr. Stickler’s psychedelic experiences.
  • Why practitioners must assess patients before psychedelic therapy.
  • Exploring consciousness as a critical aspect of well-being.
  • What science knows about how to reverse biological aging.
  • Actionable daily steps to slow down aging.
  • Dr. Sticker’s personal approach to healthy lifestyles and relationships.
  • Neurohacker Collective and Qualia nootropics for optimal brain health.

Key Links:

Episode Sponsors:

May 8, 2023

Payton Nyquvest, Founder of Numinus ketamine clinics, joins The Psychedelic Podcast to discuss psychedelic industry missteps, opportunities, & the future of communal healing.

Find episode links, summary, and transcript here.

Embracing disruptions and learning from failures are essential in the trailblazing space of psychedelics.

Encouraging industry resiliency, Payton Nyquvest, Founder, Chair, & CEO of Numinus, joins Paul F. Austin to discuss how to conquer setbacks on the path to revolutionizing mental health. Payton believes successful psychedelic leaders must adapt to real-world needs, embrace challenges, and gain conscious insights from direct experiences. Only then can innovators and practitioners create a lasting impact on the world.

Payton Nyquvest is the Founder, Chair, & Chief Executive Officer of Numinus, which empowers people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based, psychedelic-assisted therapies. He has a deep understanding of the psychedelic industry from its infancy, driven by life-saving personal experiences with multiple modalities.

At Numinus, Payton guides strategy, innovation, research, and expansion. He also supports marketing and capital-markets functions.

Highlights:

  • How Numinus aligns psychedelic therapy with real-world needs.
  • Numinus’s three-year journey from inception.
  • Numinus’s experiential training and intuitive drug development.
  • Exploring whether psychedelic therapists need first-hand experience.
  • Payton’s take on conscious leadership in psychedelic-informed business models.
  • Numinus’s collaboration with East Forest.
  • Payton’s vision for Numinus clinics and practitioner training.

Key Links:

Episode Sponsors:

May 1, 2023

Dr. Reid Robison, Chief Clinical Officer at Numinus, joins Paul F. Austin to discuss psychedelic research, legislation, & complementary modalities.

Find episode links, summary, and transcript here.

Dr. Robison shares the challenges and innovations in psychedelic therapy, drawing from his own clinical research and current projects at Numinus, a mental health company that brings safe, evidence-based psychedelic-assisted therapies to people in need.
Explore topics such as the efficacy of psychedelic-assisted therapies, the pros and cons of psychedelic patents, and the need for multimodal approaches to mental health care.

Dr. Reid Robison is a board-certified psychiatrist and Chief Clinical Officer at Numinus, where he oversees clinical services, including teaching and training in ketamine-assisted psychotherapy, for the company's clinics across the US and Canada. He has led over 200 clinical trials in neuropsychiatry and previously served as coordinating investigator for the MAPS-sponsored MDMA-assisted psychotherapy study of eating disorders.

Dr. Robison is currently principal investigator for a number of psychedelic medicine studies with psilocybin, LSD, and DMT. As a researcher and early adopter of ketamine in psychiatry, Dr. Robison got his first grant to study that medicine in 2011, around which time he also led a pivotal IV ketamine study for treatment-resistant depression.

To date, Dr. Robison has guided thousands of ketamine therapy journeys and Spravato dosing sessions, and has also worked in ayahuasca retreat settings abroad. Dr. Robison is an adjunct professor at both the University of Utah and Brigham Young University, and board chair of the Psychedelic Institute, focused on education and research.

Highlights:

  • Dr. Robison's journey into the world of psychedelics, from ketamine research to psilocybin advocacy on Capitol Hill.
  • How patents can expand access to psychedelic therapy through health insurance.
  • Dr. Robison’s innovative studies and projects at Numinus.
  • The need for a new standard of mental health care and the role of complementary modalities in achieving it.
  • Exploring modalities complementary to psychedelic therapy.
  • The promise of personalized mental health care.
  • The pioneering efforts of Numinus in offering employee psychedelic mental health care via ketamine. 
  • The future of insurance and the potential for greater coverage of ketamine-assisted psychotherapy.
  • What’s on the horizon at Numinus.

Key Links:

Episode Sponsors:

1